Landmark OS for HCC, updated IMbrave150 data - Medical Conferences
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Avastin® (bevacizumab) Clinical Trials | CC Treatment
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study - ScienceDirect
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Improved Survival with Bevacizumab in Advanced Cervical Cancer | NEJM
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Bevacizumab in the Management of Epithelial Ovarian Cancer | touchONCOLOGY
Cancers | Free Full-Text | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study | International Journal of Gynecologic Cancer
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis | BMC Cancer | Full Text
When more is better: bevacizumab treatment for patients with ovarian cancer
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
A Phase 3 Trial of Bevacizumab in Ovarian Cancer | NEJM
Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis | PLOS ONE
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma - The ASCO Post
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Avastin® (bevacizumab) Clinical Trials | NSCLC Treatment
Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial - The ASCO Post
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
